FORM 4

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject	STATE
to Section 16. Form 4 or Form 5	
obligations may continue. See	

EMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Azamian Bobak R.					2. Issuer Name and Ticker or Trading Symbol Tarsus Pharmaceuticals, Inc. [TARS]									(Check all applicable) X Director			rting Person(s) to Issuer 10% Owner		Owner	
(Last) (First) (Middle) C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160					3. Date of Earliest Transaction (Month/Day/Year) 11/09/2022								X Officer (give title Other (specify below) below) President and CEO							
(Street) IRVINE CA 92618 (City) (State) (Zip)				4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
1. Title of S	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction 2. Transaction 2. Transaction 2. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature of																			
Date (Month/Day/Ye				Execution Date,		Tr	ansa ode (l		n Disposed Of (D) (Instr. 3, 4 ar				nd 5) Securities Beneficially Owned Follov		s Illy ollowing	Form: Direct (D) or Indirect		Indirect Beneficial Ownership		
							Co	ode	v	Amou	nt	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock			11/09/202	22			S	S ⁽¹⁾		9,0	000	D	\$17.87 ⁽²⁾		1,153,106		I		By the Bobak Azamian Living Trust established April 16, 2018 ⁽³⁾	
Common Stock															1,7	50]	D		
		Tal	ole II - Derivat (e.g., pı												Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	ecution Date, iny onth/Day/Year) Transaction of Deriv 8) Secu (A) or Disproof (D) (Instr.		Deriva Securi Acquir (A) or Dispos of (D) (Instr. and 5)	tive ties ed sed	Expi (Mor	iration nth/Da	recrisable and n Date Amount of Securities Underlying Derivative Security (Ir 3 and 4) Expiration Amount of Securities Underlying Derivative Security (Ir 3 and 4)		unt of rities erlying active rity (Institute 14) Amour or Number of	r.	B. Price of Derivative Security (Instr. 5) Graph of Derivative Security Security Security Couned Followin Reporte Transac (Instr. 4)		ve es ally eg d	10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)		

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022.
- 2. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from \$17.49 to \$18.31. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Remarks:

/s/ Leonard M. Greenstein, 11/14/2022 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.